Article

The HOPE method: reverse engineering antibodies of recovered patients and bioproteins.

2022-09-27

Abstract excerpt

This is a research proposal that describes a method that attempts to use computational models to reverse engineer antibodies of recovered patients without the use of its genes found in effector B cells or the use of memory B cells samples of recovered patients. Most effector B cells are found in bone marrow and not in the serum, thus making it difficult to sample effector B cells from donors. If we concentrate on...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3a033011-14d9-54ce-b31c-0a51478c59be
DOI: 10.3897/arphapreprints.e95037

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The HOPE method: reverse engineering antibodies of recovered patients and bioproteins.DOI 10.3897/arphapreprints.e95037Read

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody librariesSemantic proximity Read

Antibodies Engineering by Computational ApproachSemantic proximity Read

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read

Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Semantic proximity Read

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.Semantic proximity Read

Cell Line Techniques and Gene Editing Tools for Antibody Production: A ReviewSemantic proximity Read

Rapid generation of potent antibodies by autonomous hypermutation in yeastSemantic proximity Read

Sagacious Epitope Selection for Vaccines, and Both Antibody-Based Therapeutics and Diagnostics: Tips From Virology and Oncology<strong> </strong>Semantic proximity Read

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeuticsSemantic proximity Read

Prompt engineering-enabled LLM or MLLM and instigative bioinformatics pave the way to identify and characterize the significant SARS-CoV-2 antibody escape mutationsSemantic proximity Read

Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human ImmunoglobulinSemantic proximity Read